Biogen Idec Inc BIIB:NASDAQ

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
329.83 -4.56   -1.36%0.00%1,319,2751.5M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. As of 03:59 PM ET 8/1/2014

Latest News Headlines for Biogen Idec Inc

Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, August 1, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.

PLEGRIDY(TM) (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis

-- Reduces Relapses, Disability Progression, and MRI Brain Lesions, with a Favorable Safety Profile Consistent with the Established Interferon Class -- -- Initial Country Launches Expected to Begin in the Coming Weeks --

Biogen Idec Second Quarter 2014 Revenues Increase -3-

attributable to Biogen Idec Inc. $714.5 $490.7 $1,194.5 $ 917.4 Adjustments: Amortization of acquired intangible assets 113.0 79.5 252.8 128.1

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

http://www.biogenidec.com/

Loading...
Bid/SizeAsk/Size
-- / ---- / --
Price OpenPrevious Close
332.93334.39
Day HighDay Low
337.82325.85
52wk High/Date52wk Low/Date
358.89 / 3/19/2014203.55 / 8/21/2013
% off 52wk High% off 52wk Low
(8.10)%62.04%
Beta (5 Yr)Market Capitalization
1.277.9B Large Cap
Shares OutstandingVolatility Avg
236.1M37.19
EPS(TTM)P/E Ratio
9.0036.7
Dividend AnnouncementDividend Yield
--0.00%
Ex-DateDate of Record
----
PayablePayable Date
0.00 - ----

Last Trade as of 8/1/2014 4:00 PM ET

Peers Information HelpBIIB Biogen Idec Inc vs. Peers

Peers 
BIIB
Biogen Idec Inc
19.61%
Johnson & Johnson
9.28%
Pfizer Inc.
-6.30%
Merck & Co., Inc.
13.37%
AbbVie Inc
-0.89%
BIIB
Biogen Idec Inc
0.00%
Johnson & Johnson
2.80%
Pfizer Inc.
3.62%
Merck & Co., Inc.
3.10%
AbbVie Inc
3.21%
BIIB
Biogen Idec Inc
-1.36%
Johnson & Johnson
-0.19%
Pfizer Inc.
0.56%
Merck & Co., Inc.
0.11%
AbbVie Inc
0.27%
Compare these stocks